Harrow (HROW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for June 18, 2026, at the company's Nashville headquarters.
Shareholders are invited to vote on key proposals, including director elections, executive compensation, and auditor ratification.
Voting matters and shareholder proposals
Election of four directors: Mark L. Baum, Adrienne L. Graves, Lauren P. Silvernail, and Perry J. Sternberg.
Advisory vote on the compensation of named executive officers.
Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and executive compensation.
Latest events from Harrow
- Proxy covers director elections, say-on-pay, auditor ratification, and strong governance practices.HROW
Proxy filing24 Apr 2026 - Double-digit growth and expanding ophthalmic launches drive strong future outlook.HROW
Leerink Global Healthcare Conference 202610 Mar 2026 - Record 36% revenue growth in 2025 sets up $350M–$365M guidance and strong momentum for 2026.HROW
Q4 20253 Mar 2026 - Q2 2024 revenue up 46% on IHEEZO and VEVYE growth; strong outlook for 2024.HROW
Q2 20242 Feb 2026 - Rapid revenue growth and new product launches position the company for strong future expansion.HROW
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - VEVYE, IHEEZO, and Triessence drive growth toward a $1B revenue target by 2027.HROW
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 revenue up 44–46% year-over-year, with strong product launches and robust outlook.HROW
Q3 202414 Jan 2026 - Prescription innovation and targeted launches drive growth, with MELT-300 as a major future catalyst.HROW
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Record revenue, margin gains, and strong outlook fueled by branded product growth.HROW
Q4 202426 Dec 2025